Impact of PSMA-PET/CT on Radiotherapy Decisions: Is There a Clinical Benefit?
- Author(s)
- Gomis-Sellés, E; Maldonado, A; Gaztañaga, M; Vera, V; Ajulia, O; Sancho, G; Siva, S; Lopez-Campos, F; Couñago, F;
- Details
- Publication Year 2025-04-17,Volume 17,Issue #8,Page 1350
- Journal Title
- Cancers
- Publication Type
- Review
- Abstract
- Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) has emerged as a game-changing imaging modality in prostate cancer, offering superior sensitivity and specificity compared to conventional imaging techniques. Its increasing adoption has significantly influenced radiotherapy decision-making, yet its true clinical impact remains under investigation. This narrative review explores the role of PSMA-PET/CT in guiding radiotherapy decisions across different clinical scenarios, from primary treatment planning to biochemical recurrence and oligometastatic disease. We assess its impact on target delineation, treatment modifications, and overall patient management while addressing existing knowledge gaps.
- Publisher
- MDPI
- Keywords
- PET-based treatment planning; Psma; androgen deprivation therapy; biochemical recurrence; metastasis-directed therapy; prostate cancer; radiotherapy; salvage radiotherapy; target volume delineation
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.3390/cancers17081350
- Open Access at Publisher's Site
https://doi.org/10.3390/cancers17081350- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-06-02 01:58:43
Last Modified: 2025-06-02 01:59:04